Personalized cancer medicine--advances and socio-economic challenges. - Wikidata - awgldk - TriplyDB

Personalized cancer medicine--advances and socio-economic challenges.

Personalized cancer medicine--advances and socio-economic challenges.

http://www.wikidata.org/entity/Q36213475

about

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users' views Whole genome sequencing for lung cancer.Forecasting Japan's physician shortage in 2035 as the first full-fledged aged society.Greater patient access to immuno-oncology therapies-what can policymakers do?Regulator of G-Protein Signaling 5 Reduces HeyA8 Ovarian Cancer Cell Proliferation and Extends Survival in a Murine Tumor Model.Latest research and treatment of advanced-stage epithelial ovarian cancer Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.

P2860

Q27016629-10FA92C8-829B-4E5B-BCB5-87A51D7DD055 Q28067753-4B9E8EE3-E7FB-4AEB-A1AF-8CC00DEA1228 Q28597904-668ABD3F-4CB4-4EE5-8D1D-D5580B75A098 Q34352229-535150C0-FFF7-4FAF-B525-CCC88BA77213 Q34509348-617733D2-859A-40F9-A658-95C97178ACAC Q35125347-EF72C5AE-9DA9-4083-ACC8-C883D16C4C86 Q36075974-4361006C-E6E1-49E1-87EF-CD271B971910 Q37206348-A97DAAE2-034E-4819-A0B6-45177CC5A5EC Q38075848-C20B88E2-617B-45D7-B7EE-A97A6D764A9B Q42085614-099B879A-E900-40FB-B8D2-79EC7354884A

P2860

Personalized cancer medicine--advances and socio-economic challenges.

http://www.wikidata.org/entity/Q36213475

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Personalized cancer medicine--advances and socio-economic challenges.

@ast

Personalized cancer medicine--advances and socio-economic challenges.

@en

type

label

Personalized cancer medicine--advances and socio-economic challenges.

@ast

Personalized cancer medicine--advances and socio-economic challenges.

@en

prefLabel

Personalized cancer medicine--advances and socio-economic challenges.

@ast

Personalized cancer medicine--advances and socio-economic challenges.

@en

P1433

Q36213475-B26419CD-AC34-4B29-8D9A-F580C63671A0

P1476

Q36213475-7D5024CB-78EB-45B3-A196-ECF8536C1200

P2093

Q36213475-9CFDCEBE-8619-46B8-B616-E4A210B2F497

Q36213475-D2E5C1EC-0894-44CA-B08E-99D0120E91F5

P2860

Q36213475-00FEA4C4-6A11-42F1-99E8-F35EA2B20006

Q36213475-1A566A78-EEB6-4F18-8662-D3BB8AB6827F

Q36213475-1AED5556-EF60-46CE-A91B-A8206AAD5C33

Q36213475-1DCD1E07-0A76-4458-BC11-A721360AFDEA

Q36213475-2237B162-D08C-4313-A1B0-236F7A148649

Q36213475-28197A9E-7154-49A9-9733-1BCC2836BA1D

Q36213475-32228817-EB8A-4B62-836E-CC7C16685E59

Q36213475-39C1BB34-67B4-4659-8109-091F16DF1E98

Q36213475-3C223937-9C4E-4B04-B9AD-4B0A348D9503

Q36213475-4288D3DB-8379-4475-B740-79F14BB25512

P304

Q36213475-A8927116-FC43-4BAE-BE74-36E8E428C63F

P31

Q36213475-4AF0A2CB-6314-4A0D-A8E9-3B2C0A258110

P356

Q36213475-54E7DC28-165A-4951-88AE-1D7D076BB3B1

P407

Q36213475-9EA26087-5C3E-4AE1-A91C-47DB7FCF3D0E

P433

Q36213475-16B99F2A-0460-4063-AD88-BB9A35390CB7

P478

Q36213475-5851B891-BFDD-4371-94CE-6B3BBDD7AC41

P577

Q36213475-7E653930-2DEE-46D8-B4C5-E3B70B39E102

P5875

Q36213475-DB9FDDE0-477C-4730-9D08-E98AAEF1C7C0

P698

Q36213475-3D5B6BD8-E28B-42E8-AC13-E2DD08BCC898

P921

Q36213475-8437DFCC-8D8A-4236-A54E-6448070A46E1

P932

Q36213475-3285CC7E-4CA8-4003-A5AB-81A0D8250E88

P356

NRCLINONC.2011.151

P1433

Nature Reviews Clinical Oncology

P1476

Personalized cancer medicine--advances and socio-economic challenges.

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

David B Jackson

http://www.w3.org/2001/XMLSchema#string

P2860

Medical Bankruptcy in the United States, 2007: Results of a National Study

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

The cancer genome

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Genome-wide genetic marker discovery and genotyping using next-generation sequencing

P304

735-741

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2011.151

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51708771

http://www.w3.org/2001/XMLSchema#string

P698

21989071

http://www.w3.org/2001/XMLSchema#string

P921

P932

3435438

http://www.w3.org/2001/XMLSchema#string